January 2012 Volume 8, Issue 1

Volume 8, Issue 1 | January 2012

January 2012

In this Issue

Research & Development

Drug Discovery News Placeholder Image

Curing from hand to mouth

Gilead Sciences acquires Pharmasset for $11 billion in hopes of more quickly advancing oral, non-interferon treatments for HCV
Drug Discovery News Placeholder Image

A positive outcome for breast cancer patients

Galena Biopharma collaborates with Genentech/Roche, HJF in clinical trials of NeuVax for prevention of breast cancer recurrences
Drug Discovery News Placeholder Image

Hands across Kendall Square

MIT and Pfizer begin work on new partnership space
Drug Discovery News Placeholder Image

The power of three

Roche, PTC Therapeutics and the SMA Foundation go after potential treatment for Spinal Muscular Atrophy
Drug Discovery News Placeholder Image

Waste not, want not

New UCSF, GE Healthcare to collaborate on umbilical cord blood project

Diagnostics

Drug Discovery News Placeholder Image

Growing steadily downstream

Affymetrix to acquire eBioscience for $330 million in plan to expand beyond discovery-based efforts
Drug Discovery News Placeholder Image

Roadmap to theranostics

Researchers awarded $3.2 million from NIH Roadmap to pioneer advanced biomolecule discovery technology
Drug Discovery News Placeholder Image

Deal aggressively targets oncology Dx

GSK and Abbott expand collaboration to develop additional companion diagnostic test for several types of cancer
Drug Discovery News Placeholder Image

MDxHealth, Celldex ink deal for brain cancer test

Companies begin Phase III study for glioblastoma multiforme test
Drug Discovery News Placeholder Image

Trauma on their minds, treatment in their thoughts

Amarantus Biosciences and Banyan Biomarkers announce traumatic brain injury research collaboration

Global News

Drug Discovery News Placeholder Image

‘The next big thing is already here’

Samsung furthers entrée into growing biosimilars market in $300 million joint venture with Biogen Idec
Drug Discovery News Placeholder Image

Good cop, bad cop, market share

Valeant shows both its amiable and hostile sides with an agreement to acquire Australia’s iNova and a hostile bid to take over U.S. company ISTA Pharmaceuticals
Drug Discovery News Placeholder Image

A ‘win, win, win’ for public-private partners

AstraZeneca launches innovative partnership with U.K.’s Medical Research Council for discontinued drug compounds
Drug Discovery News Placeholder Image

The appeal of zeal

Elan to join Cambridge in new research center aimed at neurodegenerative diseases
Drug Discovery News Placeholder Image

The eyes have it

Proximagen, Altacor to collaborate on glaucoma treatment

Omics & Systems Biology

Drug Discovery News Placeholder Image

Genes that fit everyone

NIH division paves path toward genomic medicine
Drug Discovery News Placeholder Image

Changing the channel

UCB acquires ion channel-targeting programs from Lectus Therapeutics
Drug Discovery News Placeholder Image

An alternative to whole-genome sequencing

Roche NimbleGen, BGI unveil MHC region capture technology for human disease and biomedical research
Drug Discovery News Placeholder Image

Going commercial

Compugen, DiscoveRx form collaboration to commercialize novel peptide ligands for GPCR drug targets
Drug Discovery News Placeholder Image

Bruker goes to Korea

Company will collaborate with Chungnam National University in Korea to develop reference site on glycomics methods for biopharmaceuticals and biosimilars

Commentary

Drug Discovery News Placeholder Image

Examining recent approaches to treating solid tumors

According to the Centers for Disease Control and Prevention, the top 10 cancer types are in the solid tumor category; today, the priority is likely even higher. Thus, there are clear unmet medical needs, and the development of new, cost-efficient and patient-friendly treatments remain a high priority for both the healthcare community and patients.
Drug Discovery News Placeholder Image

Out of Order: Gift horses

A quick Google search for the phrase “outcomes-based medicine” yields results in the tens of thousands. When you look at a lot of these results, however, the focus is on scientific method and not, ironically, on outcomes—which is the point of medicine, isn’t it?

Editor's Focus

Drug Discovery News Placeholder Image

Keeping our resolution to report the news

From publishing our single newspaper in January 2005 to celebrating our eighth year in 2012, ddn continues to produce many vehicles that disseminate the news.

Government Watch

Drug Discovery News Placeholder Image

Meeting the need for speed

Draft federal legislation addresses FDA issues, including faster drug approvals
Drug Discovery News Placeholder Image

A high-stakes dispute

U.S. Supreme Court hears oral arguments from Prometheus and Mayo over validity of challenged patent
Drug Discovery News Placeholder Image

Genetic testing garners lawmaker’s attention

Texas Congressman hopes to block FDA from increased regulation of laboratory-developed genetic tests

Feature

Drug Discovery News Placeholder Image

Rebooted and upgraded - SLAS2012 Show Preview

The merged ALA and SBS groups, now known as SLAS, launch first-ever joint annual meeting
Drug Discovery News Placeholder Image

The social side of SLAS2012

Events at the show and attractions in San Diego

Tools & Technology

Drug Discovery News Placeholder Image

Growth in India

AB SCIEX acquires Labindia’s mass spectrometry division to broaden presence in India
Drug Discovery News Placeholder Image

Corning Life Sciences acquires Mediatech

Corning to offer customers a more complete solution to their cell culture and bioprocess needs
Drug Discovery News Placeholder Image

Shopping for companies during the holidays

Agilent Technologies grows life- science business with strategic acquisitions in next-generation sequencing and automated analytical solutions for pharma
Drug Discovery News Placeholder Image

An unfolding development

Expedeon and Protein Discovery join forces to provide advanced products for protein research
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue